by Alex Kadhim
Researchers from the University of Lausanne and University Hospital of Zurich in Switzerland demonstrate that PD‑1–targeted CAR‑T cells can selectively reduce HIV reservoir cells and delay...
by Alex Kadhim
Researchers from leading institutions in Shanghai, China, identified a key immune signature driving steroid‑refractory acute graft‑versus‑host disease (SR‑aGvHD), involving expanded CD28+ CD8+...
by Alex Kadhim
Researchers from the Hackensack University Medical Center have demonstrated that EZH2, a chromatin-modifying epigenetic enzyme, promotes alloreactive T cell survival during graft-versus-host...
by Alex Kadhim
In a single-center phase 2 study (CAR-PRISM; NCT05767359), researchers from the Dana Farber Cancer Institute have shown that a single infusion of BCMA-directed CAR T cell therapy with...
by Alex Kadhim
Researchers at Bambino Gesù Children’s Hospital in Rome have reported that CD7 may be a viable CAR T-cell target in a subset of relapsed or refractory acute myeloid leukemia, and that...
by Alex Kadhim
Researchers at Memorial Sloan Kettering Cancer Center and City of Hope, together with a multicenter U.S. team and Poseida Therapeutics, have reported early clinical activity for a...